Barclays lowered the firm’s price target on Agilent to $125 from $135 and keeps an Underweight rating on the shares. The company issued a Big guidance cut on reset pharma and China assumptions, the analyst tells investors in a research note. The firm says China demand seems paralyzed across end markets from waiting to see what happens with stimulus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A: